SCHEMBL10116591

SCHEMBL10116591

Cc1c(NC(=O)c2ccc(NS(=O)(=O)C(C)C)cc2)ccc2c1CC(C)C2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
KDM4E B2RXH2 1/20 0.40
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
SIRT5 Q9NXA8 1/20 0.38
HPGD P15428 4/20 0.37
MAPK10 P53779 1/20 0.37
HTT P42858 1/20 0.37
ALDH1A1 P00352 3/20 0.37
MAPK1 P28482 1/20 0.37
MAPT P10636 2/20 0.36
NAMPT P43490 1/20 0.36
FLT3 P36888 1/20 0.36
HTR1F P30939 1/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116332 0.85 ALDH1A1 (0.39) LMNAKDM4ECASP3SENP8SENP7
SCHEMBL10116592 0.83 ALDH1A1 (0.44) LMNAKDM4EHPGDMAPK10HTT
SCHEMBL10116599 0.82 CASP3 (0.39) LMNAKDM4ECASP3SENP8SENP7
SCHEMBL10116567 0.81 HPGD (0.48) LMNAKDM4EHPGDHTTALDH1A1
SCHEMBL13566050 0.80 PARP1 (0.36) LMNAKDM4EHPGDHTTALDH1A1
SCHEMBL10116588 0.75 ALDH1A1 (0.41) LMNAKDM4EHPGDMAPK10ALDH1A1
SCHEMBL10116637 0.74 LMNA (0.41) LMNAKDM4EHPGDMAPK10HTT
SCHEMBL10116239 0.73 KDM4E (0.43) LMNAKDM4ECASP3SENP8SENP7
SCHEMBL10133268 0.73 KDM4E (0.43) LMNAKDM4ECASP3SENP8SENP7
SCHEMBL10116604 0.73 RAB9A (0.41) LMNAKDM4EHTTALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R LMNA 1925/4885KDM4E 1668/4885CASP3 3162/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R LMNA 2068/4885KDM4E 1627/4885CASP3 2857/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R LMNA 1857/4885KDM4E 1653/4885CASP3 3198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.